- Home
- BRIA vs CNTX Comparison
BRIA vs CNTX Comparison
Compare BRIA & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRIA
- CNTX
- Stock Information
- Founded
- BRIA 2011
- CNTX 2015
- Country
- BRIA Singapore
- CNTX United States
- Employees
- BRIA N/A
- CNTX N/A
- Industry
- BRIA
- CNTX Biotechnology: Pharmaceutical Preparations
- Sector
- BRIA
- CNTX Health Care
- Exchange
- BRIA NYSE
- CNTX Nasdaq
- Market Cap
- BRIA 76.2M
- CNTX 67.7M
- IPO Year
- BRIA 2024
- CNTX 2021
- Fundamental
- Price
- BRIA $3.02
- CNTX $0.81
- Analyst Decision
- BRIA
- CNTX Strong Buy
- Analyst Count
- BRIA 0
- CNTX 5
- Target Price
- BRIA N/A
- CNTX $6.70
- AVG Volume (30 Days)
- BRIA 15.2K
- CNTX 151.3K
- Earning Date
- BRIA 03-04-2025
- CNTX 03-20-2025
- Dividend Yield
- BRIA N/A
- CNTX N/A
- EPS Growth
- BRIA N/A
- CNTX N/A
- EPS
- BRIA 92.24
- CNTX N/A
- Revenue
- BRIA $55,755,669.00
- CNTX N/A
- Revenue This Year
- BRIA N/A
- CNTX N/A
- Revenue Next Year
- BRIA N/A
- CNTX N/A
- P/E Ratio
- BRIA $0.03
- CNTX N/A
- Revenue Growth
- BRIA 8.03
- CNTX N/A
- 52 Week Low
- BRIA $2.90
- CNTX $0.77
- 52 Week High
- BRIA $4.38
- CNTX $2.75
- Technical
- Relative Strength Index (RSI)
- BRIA N/A
- CNTX 39.82
- Support Level
- BRIA N/A
- CNTX $0.77
- Resistance Level
- BRIA N/A
- CNTX $0.87
- Average True Range (ATR)
- BRIA 0.00
- CNTX 0.08
- MACD
- BRIA 0.00
- CNTX 0.01
- Stochastic Oscillator
- BRIA 0.00
- CNTX 20.75
About BRIA BRILLIA INC
BrilliA Inc is engaged in business of sales and marketing of lingerie's products including bra, panty and body suit, mainly serving the American, European and other markets.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 ("CLDN6") x anti-CD3 bispecific antibody ("bsAb") that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.